H
Hans J.J.A. Bernsen
Publications - 6
Citations - 1900
Hans J.J.A. Bernsen is an academic researcher. The author has contributed to research in topics: Procarbazine & Lomustine. The author has an hindex of 6, co-authored 6 publications receiving 1723 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent,Antoine F. Carpentier,Alba A. Brandes,Marc Sanson,Martin J B Taphoorn,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,Laslo Sipos,H. Haaxma-Reiche,Johannes M. Kros,Mathilde C.M. Kouwenhoven,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia +16 more
TL;DR: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma, and combined loss of 1p/19q identifies a favorable subgroup of oligodENDroglial tumors.
Journal ArticleDOI
Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial
Martin J B Taphoorn,Martin J. van den Bent,Murielle Mauer,Corneel Coens,Jean-Yves Delattre,Alba A. Brandes,Peter A. E. Sillevis Smitt,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Denis Lacombe,Anouk Allgeier,Andrew Bottomley +12 more
TL;DR: The major impact of PCV on HRQOL is on nausea/vomiting, loss of appetite, and drowsiness during and shortly after treatment.
Journal ArticleDOI
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
Murielle Mauer,Martin J B Taphoorn,Andrew Bottomley,Corneel Coens,Fabio Efficace,Marc Sanson,Alba A. Brandes,Carin C.D. van der Rijt,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Denis Lacombe,Martin J. van den Bent +12 more
TL;DR: While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival, which may have implications for future use ofHRQOL as a prognostic factor for patients with cancer.
Journal ArticleDOI
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Thierry Gorlia,Jean-Yves Delattre,Alba A. Brandes,Johan M. Kros,Martin J.B. Taphoorn,Mathilde C.M. Kouwenhoven,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Denis Lacombe,Martin J. van den Bent +10 more
TL;DR: New clinical, pathological and molecular prognostic models for locally diagnosed anaplastic gliomas with oligodendroglial features are developed and showed that molecular markers added a major contribution to clinical and pathological factors in explaining PFS and OS.